Upregulation of FGFR1 expression is associated with parathyroid carcinogenesis in HPT-JT syndrome due to an HRPT2 splicing mutation

  • Authors:
    • Ji-Young Lee
    • Su Yeon Kim
    • Eun-Yeong Mo
    • Eun-Sook Kim
    • Je-Ho Han
    • Lee-So Maeng
    • An-Hee Lee
    • Jung Woo Eun
    • Suk Woo Nam
    • Sung-Dae Moon
  • View Affiliations

  • Published online on: May 29, 2014     https://doi.org/10.3892/ijo.2014.2477
  • Pages: 641-650
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Mutations of the HRPT2 gene, which are responsible for hyperparathyroidism-jaw tumor (HPT-JT) syndrome, have been implicated in the development of a high proportion of parathyroid carcinomas. The aim of this study was to investigate differences in expression of the most important genes connected with parathyroid carcinoma between HPT-JT syndrome due to an HRPT2 splicing mutation, normal parathyroid tissue and sporadic parathyroid adenoma. Total RNAs were extracted from parathyroid carcinoma in HPT-JT syndrome harbouring HRPT2 splicing mutation or sporadic parathyroid adenoma and normal parathyroid gland, and subjected to Illumina DASL-based gene expression assay. Unsupervised hierarchical clustering analysis was used to compare gene expression in HPT-JT syndrome, sporadic parathyroid adenoma and normal parathyroid glands. We identified differentially regulated genes in HPT-JT syndrome and sporadic parathyroid adenoma relative to normal parathyroid glands using a combination of Welch's t-test and fold-change analysis. Quantitative PCR, RT-PCR and IHC were used for validation. Sixteen genes differentially regulated in the parathyroid carcinoma were associated with signal pathways, MAPK, regulation of actin cytoskeleton, prostate cancer and apoptosis. FGFR1 expression was confirmed to be significantly upregulated by validation experiments. Our gene expression profiling experiments suggest that upregulated FGFR1 expression appears to be associated with parathyroid carcinoma in HPT-JT syndrome due to an HRPT2 splicing mutation.

Introduction

Hyperparathyroidism is characterized by calcium-insensitive hyper-secretion of parathyroid hormone and the development of tumors from parathyroid cells. The majority of tumors in primary hyperparathyroidism are sporadic, but ~5% are associated with hereditary cancer syndromes (1). Cases of primary hyperparathyroidism (80–85%) are due to parathyroid adenomas, and 10–15% are attributed to primary chief cell hyperplasia (2).

A molecular analysis of parathyroid hyperplasia, adenoma and carcinoma has been reported (3), and cyclin D1, calcium sensing receptor and vitamin D receptor genes are known to play a role in tumor development in parathyroid glands (4,5). Overexpression of cyclin D1, a key regulator of the cell cycle, has been implicated in the pathogenesis of 20–40% of sporadic parathyroid adenomas (6). In addition, loss of chromosome segment 1p is strongly associated with parathyroid adenoma and carcinoma, but not with hyperplasia (2,3,7,8). Other findings relevant to parathyroid pathogenesis are mutations of the HRPT2 gene (1q24-32) or MEN gene (11q13) (9,10). Germline mutations of the HRPT2 gene have been described in parathyroid carcinoma, especially in HPT-JT syndrome (1114), and have been implicated in the development of a high proportion of parathyroid carcinomas (2). Furthermore, microarray profiling has been used to examine different types of parathyroid disease, and these have proved to be excellent objects for understanding the molecular pathogenesis of the parathyroid gland (3,4). However, the molecular events involved in the formation of parathyroid tumors, especially in HPT-JT syndrome, are poorly understood. We therefore generated gene expression profiles of the main types of primary parathyroid disease: sporadic parathyroid adenoma, and parathyroid carcinoma in HPT-JT syndrome due to an HRPT2 splicing mutation (hereinafter referred to as HPT-JT syndrome). As a control we also profiled normal parathyroid tissue.

Materials and methods

Tumor samples

Fresh tumor tissues were obtained from the patient with parathyroid tumor in HPT-JT syndrome and one with a sporadic parathyroid tumor (15). As a control, normal parathyroid gland was obtained from excess tissues after routine parathyroid auto-transplantation during thyroidectomy. Sporadic parathyroid adenoma and the parathyroid tumors in HPT-JT syndrome were snap-frozen in liquid nitrogen immediately after surgery and stored at −80°C until use. The parathyroid tumor in HPT-JT syndrome was classified as a carcinoma (15), and confirmed to harbour a germ-line HRPT2 splicing mutation (15,16). The histology of the parathyroid carcinoma was classified according to the WHO guidelines (4). Patient data are summarized in Table I. Approval for this study was obtained from the Human Research Ethics Committees of the participating institutions.

Table I

Clinical and genetic data for the three patients in this study.

Table I

Clinical and genetic data for the three patients in this study.

PtAge (years)GenderCa (mg/dl)P (mg/dl)iPTH (pg/ml)Size (cm)Wt (gm)HDxHRPT2 mutation
KSN54Female9.14.3- 0.3*0.2-NormalNone
CJN57Female11.92.0624.28 3.5*2.06.0SporadicNone
KKT22Male14.11.41110.51 4.0*2.57.5HPT-JT syndromeIVS2-1G>A

[i] Pt, patient; Wt, weight; HDx, histologic diagnosis.

Preparation of RNA

Total RNA was extracted from frozen tissues using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA) and purified using Qiagen RNeasy spin columns (Qiagen, Inc., Valencia, CA) according to the protocols recommended by Illumina (San Diego, CA) for DASL applications. After DNase digestion and clean-up procedures, RNA samples were quantified, aliquoted and stored at −80°C until use. For quality control, RNA purity and integrity were evaluated by denaturing gel electrophoresis, OD 260/280 ratio and analysed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).

DASL (cDNA mediated annealing, selection, extension and ligation) assay

A 0.25–1.0 μg samples of total RNA were converted into cDNA using biotinylated random primers, oligodeoxythymidine primers and Illumina reagents. The resulting biotinylated cDNA was annealed to assay oligonucleotides and bound to streptavidin-conjugated paramagnetic particles to be able to select cDNA/oligo complexes. After oligo hybridization, mis-hybridized and non-hybridized oligos were washed away, and bound oligos were extended and ligated to generate templates for amplification with shared PCR primers. The fluorescence-labelled complementary strand was hybridized at 45°C for 18 h to Illumina HumanRef-8 DASL Expression BeadChips. After hybridization, the arrays were scanned by laser confocal microscopy using an Illumina BeadArray Reader. Array data export, processing and analysis were performed with Illumina BeadStudio v3.1.3 (Gene Expression Module V3.3.8).

Raw data preparation and statistic analysis

The exported raw array data were filtered by detection P-value <0.05 (similar to noise signals) in at least 50% of samples. We applied a filtering criterion for data analysis in which a higher signal value was required to obtain a detection P-value <0.05. The selected gene signal value was transformed by logarithm and normalized by a quantile method. Comparisons were carried out using t-tests and Benjamini-Hochberg FDR (false discovery rate) adjusted P-values (<0.05) and fold changes. Subsequently Illumina HumanRef-8 DASL Expression BeadChip expression data were re-analyzed using GenPlex software 3.0 (Istech, Inc., Korea). For primary data filtering, spots with a P-call (detection call P-value <0.1) were selected, and the remaining filtered data were used for further analysis. Quantile normalization was used to normalize data.

Unsupervised and supervised analysis

Unsupervised hierarchical clustering of log ratios was performed with Cluster 3.0, and the results were visualized with Treeview software (Stanford University, Palo Alto, CA). Pearson’s correlation, mean centering and average linkage were applied in all clustering applications. For clustering, we used average linkage clustering with standard correlation as the similarity metric. Genes within 0.5 standard deviations of the log-transformed ratios were discarded. To select specific and robust gene sets associated with the normal parathyroid gland, sporadic parathyroid adenoma and HPT-JT syndrome, we used the combination analysis with Welch’s t-test and fold-change. On Welch’s t-test and fold-change analysis, genes having P-values <0.05 and showing fold-change >2.0 were selected.

KEGG pathway analysis

Molecular pathways associated with differentially expressed genes were identified using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (http://www.genome.jp/kegg). This tool maps genes to known pathways and provides a summary of the biological processes affected. The above tool directs the specific genes to predicted pathways and provides the summary of how the biological processes have been affected. Then, the results of the biological processes were shown by a bar graph, giving the P-value <0.05 that was considered significant in KEGG.

Real-time PCR and RT-PCR

First strand cDNA was synthesized using 1 μg of total RNA, oligo(dT) and SuperScript® II Reverse Transcriptase (Invitrogen, Grand Island, NY). RT-PCR was carried out using an iCycler (Bio-Rad, Hercules, CA). The RT-PCR conditions were 95°C for 2 min, followed by 30 cycles at 95°C for 30 sec, 60°C for 30 sec, 72°C for 30 sec and 72°C for 10 min for final extension. Real-time RT-PCR for relevant genes was carried out using a SYBR-Green PCR kit (Bio-Rad) with an Mx3000P™ Real-Time PCR System (Stratagene, La Jolla, CA). The PCR primer sequences used are shown in Table II. The PCR conditions were 95°C for 10 min, followed by 45 cycles of 95°C for 15 sec, 60°C for 1 min and 72°C for 30 sec with a single fluorescence measurement. For dissociation curves, reactions were incubated at 95°C for 1 min, and lamped up from 55 to 95°C at a heating rate of 0.1°C/sec, and fluorescence was measured continuously. Gene expression was calculated according to the 2−ΔΔCt method using β-actin as an internal standard (17).

Table II

List of gene-specific primers.

Table II

List of gene-specific primers.

GenePrimer
FGFR1F: 5′-CACCCGAGGCATTATTTGAC-3′
R: 5′-AAGTTCCTCCACAGGCACAC-3′
FGF19F: 5′-AGATCAAGGCAGTCGCTCTG-3′
R: 5′-CGGATCTCCTCCTCGAAAGC-3′
FGFR2F: 5′-GACAAAGACAAGCCCAAGGA-3′
R: 5′-TGACATAGAGAGGCCCATCC-3′
RELAF: 5′-TCTGCTTCCAGGTGACAGTG-3′
R: 5′-GCCAGAGTTTCGGTTCACTC-3′
CHUKF: 5′-GAAGGTGCAGTAACCCCTCA-3′
R: 5′-ATTGCCCTGTTCCTCATTTG-3′
NTRK1F: 5′-GGACAACCCTTTCGAGTTCA-3′
R: 5′-CAAGGAGCAGCGTAGAAAGG-3′
TCF7F: 5′-CCTTGATGCTAGGTTCTGGTG-3′
R: 5′-GCTTCTTGATGGTTGGCTTC-3′
FGF3F: 5′-AGATAACGGCAGTGGAGGTG-3′
R: 5′-ATTATAGCCCAGCTCGTGGA-3′
CACNA1AF: 5′-AGTGAACAAAAACGCCAACC-3′
R: 5′-AAAGTAGCGCAGGTTCAGGA-3′
FGF22F: 5′-TTCTACGTGGCCATGAACCG-3′
R: 5′-GTGTTGTGGCCGTTCTCTTC-3′
β-actinF: 5′-GAGCTACGAGCTGCCTGAC-3′
R: 5′-GGATGCCACAGGACTCCA-3′
PLCB4F: 5′-ATCTGGAAGGGCGGATAGTT-3′
R: 5′-CATTGGACTGACGTTGTTGG-3′
CAMK2DF: 5′-AAGGGTGCCATCTTGACAAC-3′
R: 5′-TGCTTTCGTGCTTTCACATC-3′
FGF1F: 5′-TCAGAGGACATGGCAAGGTA-3′
R: 5′-GGGAATGTCCCCAGGTTAAT-3′
IL1BF: 5′-TCCAGGGACAGGATATGGAG-3′
R: 5′-TCTTTCAACACGCAGGACAG-3′
FGF7F: 5′-CAGTGGCAGTTGGAATTGTG-3′
R: 5′-CCTCCGTTGTGTGTCCATTT-3′
TRAF2F: 5′-ACCAAGCTGGAAGCCAAGTA-3′
R: 5′-GTGAACACAGGCAGCACAGT-3′
MAPK10F: 5′-CTTCCCAGATTCCCTCTTCC-3′
R: 5′-GCTGGGTCATACCAGACGTT-3′
FGF17F: 5′-CAGATCCGCGAGTACCAACT-3′
R: 5′-TCACTCTCAGCCCCTTTGAT-3′
FGFR4F: 5′-TTTCCCCTATGTGCAAGTCC-3′
R: 5′-GTAGGAGAGGCCGATGGAAT-3′
CACNA1HF: 5′-TACTCGTTGGACGGACACAA-3′
R: 5′-AAGCACAGCAGAAGGACGTT-3′
Immunohistochemistry (IHC)

Tissues were processed for paraffin embedding, and 3-μm sections were prepared and mounted on glass slides. The mounted sections were pretreated with 10 mM sodium citric acid at 95°C for 10 min for antigen retrieval, and then with 0.3% H2O2 in methanol for 30 min to permeabilize them. The sections were blocked using 2.5% horse serum, and then incubated with rabbit anti-FGFR1 antibody (Cell Signaling, Danvers, MA). After rinsing, they were incubated sequentially in biotinylated anti-rabbit antibody and then with ABC complex (Vector, Burlingame, CA) for 1 h at room temperature. Immunoreactivity was visualized by incubation in 3′,3-diaminobenzidine (DAB) solution (Vector) for 50 sec at room temperature. The sections were counterstained with Harris haematoxylin, dehydrated, cleared, mounted and viewed under a light microscope (AX70; Olympus, Tokyo, Japan). For immunofluorescence assays, the mounted sections were blocked with 2.5% horse serum, and incubated with rabbit anti-FGFR1 antibody (Cell Signaling). After rinsing, they were incubated with anti-rabbit antibody. Nuclei were stained with 4′,6-diamino-2-phenylindole (DAPI) (ImmunoBioscience, Santa Clara, CA) and viewed under a fluorescence microscopy (Axiovert 200, Carl Zeiss, Oberkochen, Germany).

Results

Transcriptome scans identified large-scale gene expression changes between HPT-JT syndrome, sporadic parathyroid adenoma and normal parathyroid gland

Initially we performed a molecular classification analysis to determine whether our spotted-oligonucleotide microarray system was able to differentiate HPT-JT syndrome, sporadic parathyroid adenoma, and normal parathyroid gland by molecular profiling. We conducted an average linkage unsupervised hierarchical clustering analysis. In Fig. 1A red and green indicate transcript expression levels above and below the median of the sample. We selected 5697 genes (>+2-fold, 3375 and <−2-fold, 2322 genes, P<0.05) in HPT-JT syndrome and 5328 genes (>+2-fold, 3345 and <−2-fold, 1983 genes, P<0.05) in sporadic parathyroid adenoma relative to normal parathyroid gland according to the minimal filtering criteria (Fig. 1B). Venn diagram analysis of gene signatures common to HPT-JT syndrome and sporadic parathyroid adenoma revealed that 2065 of the genes were de-regulated relative to the normal parathyroid gland only in HPT-JT syndrome, and 1696 genes only in sporadic parathyroid adenoma (Fig. 1C). These data suggest that thousands of genes either contributed to or were affected by the development of tumor in parathyroid gland.

Identification of molecular signature in HPT-JT syndrome and sporadic parathyroid adenoma

By applying the combination of Welch’s t-test and fold-change analysis to the microarray data, we identified an upregulated specific molecular signature of 1101 genes in HPT-JT syndrome, and a downregulated specific molecular signature of 964 genes. Similarly we obtained an upregulated specific molecular signature of 1071 genes in sporadic parathyroid adenoma and a downregulated specific molecular signature of 625 genes. A total of 2274 genes were upregulated in both HPT-JT syndrome and sporadic parathyroid adenoma, and 1358 genes were downregulated in both (Fig. 1C).

Identification of the molecular pathways in HPT-JT syndrome and sporadic parathyroid adenoma

Using the pathway mining tool in the KEGG pathway database we characterized the biological processes in which the 2065 genes in the HPT-JT syndrome signature and the 1696 genes in the sporadic parathyroid adenoma signature participated (Fig. 2). MAPK, regulation of actin, and calcium signaling pathways were the most significant signaling pathways associated specifically with HPT-JT syndrome (Fig. 2A), while calcium signaling, MAPK and, insulin signaling were the most significant signaling pathways associated with sporadic parathyroid adenoma (Fig. 2B). We sub-classified, according to KEGG, 16 of the genes associated with pathways that were specifically de-regulated in HPT-JT syndrome (Fig. 2C), and 15 of the genes in sporadic parathyroid adenoma (Fig. 2D). In Fig. 2C and D solid and open bars represent genes up- or downregulated, respectively. Genes overexpressed only in HPT-JT syndrome were FGFR1, FGF19, FGFR2, RELA, CHUK, MKNK2 and NFATC4, and genes underexpressed only in HPT-JT syndrome were FGF22, CACNA1A, FGF3, TCF7, NTRK1, EGFR, CACNA1G, ATF4 and FGF12. The PLCB4, CAMK2D, FGF1, TNF, IL1B, FGF7, PHKB, PRKAR2A and IRAK1 were overexpressed only in sporadic parathyroid adenoma, while CACNA1H, FGFR4, FGF17, MAPK10, TRAF2 and CAMK2B were underexpressed. It is evident that the genes de-regulated in HPT-JT syndrome are quite different from those de-regulated in sporadic parathyroid adenoma (Tables III and IV).

Table III

Significant de-regulated pathways and genes associated with HPT-JT syndrome.

Table III

Significant de-regulated pathways and genes associated with HPT-JT syndrome.

KEGG pathway (HPT-JT syndrome)GenesaP-value
MAPK signaling pathwayFGFR1, FGF19, FGFR2, CHUK, MKNK2, NFATC4, FGF12, ATF4, CACNA1G, EGFR, NTRK1, FGF3, CACNA1A, FGF220
Regulation of actin cytoskeletonFGFR1, FGF19, FGFR2, FGF12, EGFR, FGF3, FGF229.48E-10
Prostate cancerFGFR1, FGFR2, RELA, CHUK, ATF4, EGFR, TCF72.99E-08
ApoptosisRELA, CHUK, NTRK11.85E-08
Significant de-regulated pathways and genes associated with sporadic parathyroid adenoma.

KEGG pathway (sporadic parathyroid adenoma)GenesaP-value
Calcium signaling pathwayPLCB4, CAMK2D, PHKB, CAMK2B, CACNA1H0
MAPK signaling pathwayFGF1, TNF, IL1B, FGF7, TRAF2, MAPK10, FGF17, FGFR4, CACNA1H3.51E-14
Insulin signaling pathwayPHKB, PRKAR2A, MAPK106.41E-09
ApoptosisTNF, IL1B, PRKAR2A, IRAK1, TRAF22.09E-10
Wnt signaling pathwayPLCB4, CAMK2D, CAMK2B, MAPK101.07E-06
Regulation of actin cytoskeletonFGF1, FGF7, FGF17, FGFR43.51E-05
Toll-like receptor signaling pathwayTNF, IL1B, IRAK1, MAPK102.45E-07

a Bold character, upregulated genes.

Table IV

Genes frequently de-regulated in HPT-JT syndrome.

Table IV

Genes frequently de-regulated in HPT-JT syndrome.

UnigeneSymbolGene nameFold changeaMolecular function
Hs.264887FGFR1Fibroblast growth factor receptor 11.81Mitogenesis and differentiation
Hs.249200FGF19Fibroblast growth factor 191.74Tumor growth and invasion
Hs.533683FGFR2Fibroblast growth factor receptor 21.36Mitogenesis and differentiation
Hs.502875RELAv-rel reticuloendotheliosis viral oncogene homolog A (avian)1.35Ubiquitous transcription factor
Hs.198998CHUKConserved helix-loop-helix ubiquitous kinase1.33Ubiquination pathway, thereby activating the transcription factor
Hs.515032MKNK2MAP kinase interacting serine/threonine kinase 21.28Oncogenic transformation and malignant cell proliferation
Hs.77810NFATC4Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 41.28A member of the nuclear factors of activated T cells DNA-binding transcription complex
Hs.584758FGF12Fibroblast growth factor 12−1.50Regulate cardiac Na(+) and Ca(2+) channel currents
Hs.496487ATF4Activating transcription factor 4−1.50Encodes a transcription factor
Hs.591169CACNA1GCalcium channel, voltage-dependent, T type, α 1G subunit−1.63Cell motility, cell division and cell death
Hs.488293EGFREpidermal growth factor receptor−1.81Cell proliferation
Hs.406293NTRK1Neurotrophic tyrosine kinase, receptor, type 1−2.00Cell differentiation
Hs.573153TCF7Transcription factor 7 (T-cell specific, HMG-box)−2.30Lymphocyte differentiation
Hs.37092FGF3Fibroblast growth factor 3−3.05Cell growth, morphogenesis, tissue repair, tumor growth and invasion
Hs.501632CACNA1ACalcium channel, voltage-dependent, P/Q type, α 1A subunit−3.21Hormone or eurotransmitter release and gene expression
Hs.248087FGF22Fibroblast growth factor 22−4.19Cell growth, morphogenesis, tissue repair, tumor growth and invasion
Genes frequently de-regulated in sporadic parathyroid adenoma.

UnigeneSymbolGene nameFold changeaMolecular function
Hs.472101PLCB4Phospholipase C, β 42.29Intracellular transduction of many extracellular signals in the retina
Hs.144114CAMK2D Calcium/calmodulin-dependent protein kinase (CaM kinase) II δ2.22Alternative splicing results in multiple transcript variants
Hs.483635FGF1Fibroblast growth factor 11.88Embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion
Hs.241570TNFTumor necrosis factor1.86Cell proliferation, differentiation, apoptosis, lipid metabolism and coagulation
Hs.126256IL1BInterleukin 1, β1.56Cell proliferation, differentiation and apoptosis
Hs.567268FGF7Fibroblast growth factor 71.41Embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion
Hs.78060PHKBPhosphorylase kinase, β1.29The δ subunit mediates the depen- dence of the enzyme on calcium concentration
Hs.631923PRKAR2AProtein kinase, cAMP-dependent, regulatory, type II, α1.28Regulate protein transport from endosomes to the Golgi apparatus and further to the endoplasmic reticulum (ER)
Hs.522819IRAK1Interleukin-1 receptor-associated kinase 11.23IL1-induced upregulation of the transcription factor NF-κB
Hs.351887CAMK2B Calcium/calmodulin-dependent protein kinase (CaM kinase) II β−1.34Different cellular localizations and interact differently with calmodulin
Hs.522506TRAF2TNF receptor-associated factor 2−1.45Mediator of the anti-apoptotic signals from TNF receptors
Hs.125503MAPK10Mitogen-activated protein kinase 10−1.56Proliferation, differentiation, trans-cription regulation and development
Hs.248192FGF17Fibroblast growth factor 17−1.78Embryonic development cell growth, morphogenesis, tissue repair, tumor growth and invasion
Hs.165950FGFR4Fibroblast growth factor receptor 4−2.28Mitogenesis and differentiation
Hs.459642CACNA1HCalcium channel, voltage-dependent, T type, α 1H subunit−2.39Influx of calcium ions into the cell upon membrane polarization

a Ratio of log2-transformed mean expression values (HPT-JT syndrome vs. normal parathyroid gland).

a Ratio of log2-transformed mean expression values (sporadic parathyroid adenoma vs. normal parathyroid gland).

Experimental validation of the molecular signature in HPT-JT syndrome and sporadic parathyroid adenoma using comparative real-time PCR and RT-PCR

In order to validate the gene expression data obtained by the DASL-assay, we selected the genes highly de-regulated in both HPT-JT syndrome and sporadic parathyroid adenoma shown in Fig. 2C and D, and performed comparative real-time reverse transcriptase-PCR analysis and RT-PCR. Levels of transcription of 10 selected genes up- and downregulated in HPT-JT syndrome are shown in Fig. 3A and B, respectively, and those of 10 genes up- and downregulated in sporadic parathyroid adenoma in Fig. 3C and D. Comparative real-time RT-PCR data showed that FGFR1, FGFR2, FGF19, RELA and CHUK were upregulated in HPT-JT syndrome relative to sporadic parathyroid adenoma, in good agreement with the microarray data (Fig. 2C). Similarly NTRK1 and FGF22 were downregulated in agreement with the microarray data, but the findings for TCF7, FGF3, CACNA1A were ambiguous, and their levels of expression were low (Figs. 3B and 4A). In sporadic parathyroid adenoma, the genes for PLCB4, FGF1, IL1B, FGF7, MAPK10, FGFR4 did not differ significantly between the two samples, whereas for CAMK2D, TRAF2, FGF17, CACNA1H the data of real-time PCR and RT-PCR conflicted with the microarray findings (Figs. 3C and D, 4A). The most highly expressed gene in HPT-JT syndrome, FGFR1, was further validated by immunohistochemistry. Immunohistochemical staining with FGFR1 antibody revealed strong expression in HPT-JT syndrome, but no detectable expression in sporadic parathyroid adenoma or normal parathyroid gland (Fig. 4B). The finding that FGFR1 protein expression was significantly upregulated in HPT-JT syndrome suggests that FGFR1 does indeed play a role in parathyroid carcinogenesis.

Discussion

Parathyroid carcinoma is a rare malignant tumor responsible for less than 1% of cases of hyperparathyroidism. An increased incidence of this carcinoma has been reported in patients with HPT-JT syndrome (2). The incidence of parathyroid carcinoma in HPT-JT syndrome is reported to be as high as 15% (18,19). Germline mutations of the HRPT2 gene have been described in parathyroid carcinoma and in HPT-JT parathyroid carcinoma syndrome (1114), but the function of the HRPT2 gene is unknown. Previously, we were able to amplify the mutated allele generated by a splice acceptor site mutation of HRPT2 in HPT-JT syndrome (15), and we quantified the aberrantly spliced HRPT2 mRNA resulting from the splicing abnormality by real-time RT-PCR (16). Loss of HRPT2 expression was found to alter the expression of several target genes that are associated with cell growth and cell death (20).

In this study, to clarify the molecular mechanisms involved in the development of parathyroid carcinomas in HPT-JT syndrome harbouring a splicing HRPT2 mutation, we undertook gene expression profiling using Illumina DASL matrices. We identified sixteen genes in the HPT-JT syndrome involved in regulation of MAPK signaling, regulation of actin cytoskeleton, prostate cancer and apoptosis pathways, and 15 genes in sporadic parathyroid adenoma involved in calcium signaling, MAPK signaling, insulin signaling, apoptosis and Wnt signaling (Fig. 2, Table III). Our data suggest that increased expression of fibroblast growth factor receptor type 1 (FGFR1) is highly relevant to parathyroid carcinogenesis in HPT-JT syndrome harbouring an HRPT2 splicing mutation. FGF signaling mediated by FGFR involves a classic receptor tyrosine kinase signaling pathway and its de-regulation at various points can result in malignancy (21). FGF signaling is involved in multiple developmental processes including embryonic mesodermal patterning (22). In the adult, it contributes to tissue homeostasis, as well as tissue repair, angiogenesis and inflammation (23,24). Elevated levels of FGFR1 have been found in a number of cancers, including prostate, breast and sarcoma (2528). One study detected frequent focal amplification of FGFR1 in non-small cell lung carcinoma cell lines, and these cell lines were dependent on FGFR1 activity for growth (29,30). FGFR1 is frequently upregulated in prostate cancer (29,31). Klotho, which is expressed in the kidney, pituitary and parathyroid glands, converts FGFR1 (a canonical receptor for various FGFs) into a specific receptor for FGF-23 (32,33). The parathyroid cells expressing Klotho and FGFR1 are responsive to FGF-23, both in vivo and in vitro (33,34). However, studies on FGFR-Klotho signaling in parathyroid glands show conflicting results (33). One current hypothesis suggests that FGFR1 upregulation destroys the subtle interplay between epithelial and mesenchymal cells (30), and FGFR1 has also been suggested to have tumor suppressor properties, since downregulated expression of FGFR2 in particular has been found in many cancers (21,3537). However, it is not clear whether FGFR2 is a tumor suppressor, since it is also found to be upregulated in gastric, pancreatic and lung cancers (21). Further studies are necessary to clarify the role of FGFR1 in parathyroid glands. Our results may provide insight into the pathogenesis of parathyroid neoplasia in the HPT-JT syndrome.

In summary, our gene expression profiling experiments suggest that upregulation of FGFR1 expression is associated with parathyroid carcinogenesis in HPT-JT syndrome due to an HRPT2 splicing mutation. Hence FGF signaling molecules may provide useful targets for treatment.

Acknowledgements

This study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0008886).

References

1 

Starker LF, Akerstrom T, Long WD, et al: Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. Horm Cancer. 3:44–51. 2012. View Article : Google Scholar : PubMed/NCBI

2 

DeLellis RA: Parathyroid carcinoma: an overview. Adv Anat Pathol. 12:53–61. 2005. View Article : Google Scholar

3 

Hunt JL, Carty SE, Yim JH, Murphy J and Barnes L: Allelic loss in parathyroid neoplasia can help characterize malignancy. Am J Surg Pathol. 29:1049–1055. 2005.PubMed/NCBI

4 

Haven CJ, Howell VM, Eilers PH, et al: Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. 64:7405–7411. 2004. View Article : Google Scholar : PubMed/NCBI

5 

Yano S, Sugimoto T, Tsukamoto T, et al: Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol. 148:403–411. 2003. View Article : Google Scholar : PubMed/NCBI

6 

Arnold A, Shattuck TM, Mallya SM, et al: Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res. 17(Suppl 2): N30–N36. 2002.PubMed/NCBI

7 

Szabo E, Carling T, Hessman O and Rastad J: Loss of heterozygosity in parathyroid glands of familial hypercalcemia with hypercalciuria and point mutation in calcium receptor. J Clin Endocrinol Metab. 87:3961–3965. 2002. View Article : Google Scholar : PubMed/NCBI

8 

Valimaki S, Forsberg L, Farnebo LO and Larsson C: Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol. 21:727–735. 2002.PubMed/NCBI

9 

Cetani F, Pardi E, Giovannetti A, et al: Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian kindreds with familial isolated hyperparathyroidism. Clin Endocrinol (Oxf). 56:457–464. 2002. View Article : Google Scholar : PubMed/NCBI

10 

Tanaka C, Uchino S, Noguchi S, et al: Biallelic inactivation by somatic mutations of the MEN1 gene in sporadic parathyroid tumors. Cancer Lett. 175:175–179. 2002. View Article : Google Scholar : PubMed/NCBI

11 

Cetani F, Pardi E, Borsari S, et al: Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 89:5583–5591. 2004. View Article : Google Scholar

12 

Hobbs MR, Pole AR, Pidwirny GN, et al: Hyperpara-thyroidism- jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q. Am J Hum Genet. 64:518–525. 1999. View Article : Google Scholar : PubMed/NCBI

13 

Howell VM, Haven CJ, Kahnoski K, et al: HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet. 40:657–663. 2003. View Article : Google Scholar : PubMed/NCBI

14 

Shattuck TM, Valimaki S, Obara T, et al: Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 349:1722–1729. 2003. View Article : Google Scholar : PubMed/NCBI

15 

Moon SD, Park JH, Kim EM, et al: A Novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 90:878–883. 2005.

16 

Moon S, Kim JH, Shim JY, et al: Analysis of aberrantly spliced HRPT2 transcripts and the resulting proteins in HPT-JT syndrome. Mol Genet Metab. 100:365–371. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.

18 

Carpten JD, Robbins CM, Villablanca A, et al: HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 32:676–680. 2002. View Article : Google Scholar : PubMed/NCBI

19 

Hewitt KM, Sharma PK, Samowitz W and Hobbs M: Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann Otol Rhinol Laryngol. 116:928–933. 2007. View Article : Google Scholar : PubMed/NCBI

20 

Wang P, Bowl MR, Bender S, et al: Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice. Mol Cell Biol. 28:2930–2940. 2008. View Article : Google Scholar : PubMed/NCBI

21 

Ahmad I, Iwata T and Leung HY: Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta. 1823:850–860. 2012. View Article : Google Scholar : PubMed/NCBI

22 

De Moerlooze L, Spencer-Dene B, Revest JM, Hajihosseini M, Rosewell I and Dickson C: An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development. 127:483–492. 2000.PubMed/NCBI

23 

Turner N and Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Haugsten EM, Wiedlocha A, Olsnes S and Wesche J: Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 8:1439–1452. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Kwabi-Addo B, Ozen M and Ittmann M: The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 11:709–724. 2004. View Article : Google Scholar : PubMed/NCBI

26 

Freier K, Schwaenen C, Sticht C, et al: Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 43:60–66. 2007. View Article : Google Scholar : PubMed/NCBI

27 

Meyer KB, Maia AT, O’Reilly M, et al: Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 6:e1082008. View Article : Google Scholar : PubMed/NCBI

28 

Jacquemier J, Adelaide J, Parc P, et al: Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer. 59:373–378. 1994. View Article : Google Scholar : PubMed/NCBI

29 

Murphy T, Darby S, Mathers ME and Gnanapragasam VJ: Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol. 220:452–460. 2010.PubMed/NCBI

30 

Acevedo VD, Gangula RD, Freeman KW, et al: Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 12:559–571. 2007. View Article : Google Scholar : PubMed/NCBI

31 

Armstrong K, Ahmad I, Kalna G, et al: Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. Br J Cancer. 105:1362–1369. 2011. View Article : Google Scholar : PubMed/NCBI

32 

Urakawa I, Yamazaki Y, Shimada T, et al: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 444:770–774. 2006. View Article : Google Scholar : PubMed/NCBI

33 

Imanishi Y, Nagata Y and Inaba M: Parathyroid diseases and animal models. Front Endocrinol (Lausanne). 3:782012.

34 

Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al: The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 117:4003–4008. 2007.PubMed/NCBI

35 

Amann T, Bataille F, Spruss T, et al: Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am J Pathol. 176:1433–1442. 2010. View Article : Google Scholar : PubMed/NCBI

36 

Diez de Medina SG, Chopin D, El Marjou A, et al: Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene. 14:323–330. 1997.PubMed/NCBI

37 

Naimi B, Latil A, Fournier G, Mangin P, Cussenot O and Berthon P: Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate. 52:245–252. 2002. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August-2014
Volume 45 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lee J, Kim SY, Mo E, Kim E, Han J, Maeng L, Lee A, Eun JW, Nam SW, Moon S, Moon S, et al: Upregulation of FGFR1 expression is associated with parathyroid carcinogenesis in HPT-JT syndrome due to an HRPT2 splicing mutation. Int J Oncol 45: 641-650, 2014.
APA
Lee, J., Kim, S.Y., Mo, E., Kim, E., Han, J., Maeng, L. ... Moon, S. (2014). Upregulation of FGFR1 expression is associated with parathyroid carcinogenesis in HPT-JT syndrome due to an HRPT2 splicing mutation. International Journal of Oncology, 45, 641-650. https://doi.org/10.3892/ijo.2014.2477
MLA
Lee, J., Kim, S. Y., Mo, E., Kim, E., Han, J., Maeng, L., Lee, A., Eun, J. W., Nam, S. W., Moon, S."Upregulation of FGFR1 expression is associated with parathyroid carcinogenesis in HPT-JT syndrome due to an HRPT2 splicing mutation". International Journal of Oncology 45.2 (2014): 641-650.
Chicago
Lee, J., Kim, S. Y., Mo, E., Kim, E., Han, J., Maeng, L., Lee, A., Eun, J. W., Nam, S. W., Moon, S."Upregulation of FGFR1 expression is associated with parathyroid carcinogenesis in HPT-JT syndrome due to an HRPT2 splicing mutation". International Journal of Oncology 45, no. 2 (2014): 641-650. https://doi.org/10.3892/ijo.2014.2477